Direct comparison
Exclusive vs. Non-Exclusive License
Exclusive vs. non-exclusive license compared: rights granted, royalty rates, diligence obligations, best-fit technologies, and march-in-rights exposure.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about Exclusive vs. Non-Exclusive License
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Exclusive License, Non-Exclusive License compare side by side?
The table below compares Exclusive License, Non-Exclusive License across 13 procurement-relevant dimensions, from number of licensees through common hybrid variant.
Side-by-side comparison
| Dimension | Exclusive License | Non-Exclusive License |
|---|---|---|
| Number of licensees | One licensee only; institution typically also gives up its own commercial-use right (though research/education-use carve-outs are common) | Multiple licensees can hold rights to the same technology simultaneously |
| Typical royalty rate | Higher per-licensee rate; academic median around 3% of net sales per a 2023 PLOS ONE study, reported ranges roughly 1%-10%, directional only | Lower per-licensee rate, often offset by royalty income from multiple licensees |
| Diligence/milestone obligations | Typically heavy -- development plan, dated milestones, progress reports, minimum spending, remedy for missed milestones | Typically minimal or none, since the institution hasn't foreclosed licensing to a more active party |
| Best-fit technology | Early-stage, capital-intensive technology requiring years of investment (e.g. a drug candidate); the basis for a single spinout company | Broadly applicable technology used by many parties -- research tools, reagents, platform software, materials |
| Bayh-Dole march-in exposure | Applies -- 35 U.S.C. Section 203 lets the funding agency compel additional licensing under four narrow statutory conditions if the licensee fails to commercialize | Not a practical concern -- multiple licensees already using the technology inherently addresses the government's practical-application interest |
| Sublicensing | Common, but only if separately granted in the agreement -- not automatic | Less common; each party typically holds only its own direct license |
| Startup / VC investment case | Usually necessary -- investors want protection from a competitor licensing the same IP | Rarely required -- there is no multi-year development gap to protect |
| Typical negotiating leverage for the institution | Higher -- equity, higher royalties and milestone payments can be extracted in exchange for exclusivity | Lower per deal -- value comes from the volume of licensees rather than per-deal leverage |
| 35 U.S.C. Section 204 U.S.-manufacturing preference | Applies -- an exclusive U.S. licensee generally must agree to manufacture substantially in the U.S. (agency-waivable) | Does not apply |
| Administrative burden | Fewer relationships per technology, but higher-stakes monitoring of one licensee's diligence | More simultaneous relationships, but lighter monitoring per licensee |
| Revenue model | Larger potential per-deal royalty or equity, concentrated in a single outcome | Smaller per-deal royalty, aggregated across many licensees |
| Risk if the licensee underperforms | High -- the technology can sit undeveloped and unavailable to anyone else absent reversion rights | Low -- other licensees, and new ones, remain available regardless |
| Common hybrid variant | Field-of-use or territory-limited exclusivity; time- or diligence-conditioned exclusivity | N/A -- non-exclusivity is already the more flexible default |
Common questions
Common questions about Exclusive License vs Non-Exclusive License
Can a license start non-exclusive and convert to exclusive later?
+
Yes. Some agreements use an option or evaluation-license structure that converts to exclusive if the licensee meets defined conditions, such as a funding or development milestone. The reverse also happens: an exclusive license can convert to non-exclusive as the contractual remedy for a licensee that misses its diligence milestones.
Does an exclusive license always produce more total revenue for the institution?
+
Not necessarily. An exclusive license typically commands a higher rate per licensee, but a non-exclusive strategy can generate comparable or greater aggregate royalty income across multiple licensees for a broadly applicable technology. The right structure depends on which approach actually gets the technology developed and used.
What is a sole license, and how is it different from an exclusive license?
+
A sole license permits only one commercial licensee, like an exclusive license, but the institution retains its own right to practice the technology -- a right a true exclusive license typically forecloses.
Is a field-of-use-limited exclusive license the same as a non-exclusive license?
+
No. A field-of-use restriction limits what the exclusive licensee can do with the technology (for example, only within veterinary diagnostics), but within that defined field the licensee is still the sole rights-holder. The institution can grant a separate exclusive license to a different party in a different field, but neither of those licenses is non-exclusive with respect to the field it actually covers.
Who decides whether a given invention should be licensed exclusively or non-exclusively?
+
The technology transfer office typically makes this call based on the nature of the technology, the size of the addressable market, and how much upfront investment a licensee will need to make before the technology reaches practical use -- see CASRAI's Patent Licensing guide for how startup versus established-company negotiating leverage factors into that decision.
